Sacubitril/valsartan: A new paradigm in heart failure

Sunil Pai, Priyanka Kamath

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Heart failure (HF) is a syndrome whose cardinal symptoms are dyspnea and fatigue leading to a progressive decrease in exercise capacity. Drugs currently used include angiotensin-converting-enzyme inhibitors, angiotensin receptor blockers (ARB), diuretics, alone or in combination, and in the cases where indicated, digoxin. Sacubitril/valsartan represents a new approach to treatment since the drug complex is made up of moieties of sacubitril, a neprilysin inhibitor and valsartan, an ARB. Since sacubitril and valsartan, inhibit neprilysin and block the angiotensin receptor, respectively, the drug molecule can be considered to play a central role by causing a dual inhibition of both the pathways that play an important role in the pathogenesis of HF. It was approved in July 2015 by the US Food and Drug Administration to reduce the risk of cardiovascular death and hospitalization for HF in patients with chronic HF (NYHA Class II-IV) and reduced ejection fraction. Symptomatic hypotension and angioedema were the major side effects reported from clinical trials. The trials are currently being done to study its effects in HF preserved ejection fraction, chronic kidney disease, and aortic stiffness; the results of which are awaited.

Original languageEnglish
Pages (from-to)37-40
Number of pages4
JournalAsian Journal of Pharmaceutical and Clinical Research
Volume9
Issue number4
Publication statusPublished - 01-07-2016

Fingerprint

Heart Failure
Neprilysin
Angiotensin Receptor Antagonists
Valsartan
Pharmaceutical Preparations
Angioedema
Vascular Stiffness
Angiotensin Receptors
Digoxin
United States Food and Drug Administration
Chronic Renal Insufficiency
Angiotensin-Converting Enzyme Inhibitors
Diuretics
Dyspnea
Hypotension
Fatigue
Hospitalization
LCZ 696
Clinical Trials
Exercise

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science
  • Pharmacology (medical)

Cite this

Pai, Sunil ; Kamath, Priyanka. / Sacubitril/valsartan : A new paradigm in heart failure. In: Asian Journal of Pharmaceutical and Clinical Research. 2016 ; Vol. 9, No. 4. pp. 37-40.
@article{1dbe9f7172694bbab12bebaa179a6001,
title = "Sacubitril/valsartan: A new paradigm in heart failure",
abstract = "Heart failure (HF) is a syndrome whose cardinal symptoms are dyspnea and fatigue leading to a progressive decrease in exercise capacity. Drugs currently used include angiotensin-converting-enzyme inhibitors, angiotensin receptor blockers (ARB), diuretics, alone or in combination, and in the cases where indicated, digoxin. Sacubitril/valsartan represents a new approach to treatment since the drug complex is made up of moieties of sacubitril, a neprilysin inhibitor and valsartan, an ARB. Since sacubitril and valsartan, inhibit neprilysin and block the angiotensin receptor, respectively, the drug molecule can be considered to play a central role by causing a dual inhibition of both the pathways that play an important role in the pathogenesis of HF. It was approved in July 2015 by the US Food and Drug Administration to reduce the risk of cardiovascular death and hospitalization for HF in patients with chronic HF (NYHA Class II-IV) and reduced ejection fraction. Symptomatic hypotension and angioedema were the major side effects reported from clinical trials. The trials are currently being done to study its effects in HF preserved ejection fraction, chronic kidney disease, and aortic stiffness; the results of which are awaited.",
author = "Sunil Pai and Priyanka Kamath",
year = "2016",
month = "7",
day = "1",
language = "English",
volume = "9",
pages = "37--40",
journal = "Asian Journal of Pharmaceutical and Clinical Research",
issn = "0974-2441",
publisher = "Innovare Academics Sciences Pvt. Ltd",
number = "4",

}

Sacubitril/valsartan : A new paradigm in heart failure. / Pai, Sunil; Kamath, Priyanka.

In: Asian Journal of Pharmaceutical and Clinical Research, Vol. 9, No. 4, 01.07.2016, p. 37-40.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Sacubitril/valsartan

T2 - A new paradigm in heart failure

AU - Pai, Sunil

AU - Kamath, Priyanka

PY - 2016/7/1

Y1 - 2016/7/1

N2 - Heart failure (HF) is a syndrome whose cardinal symptoms are dyspnea and fatigue leading to a progressive decrease in exercise capacity. Drugs currently used include angiotensin-converting-enzyme inhibitors, angiotensin receptor blockers (ARB), diuretics, alone or in combination, and in the cases where indicated, digoxin. Sacubitril/valsartan represents a new approach to treatment since the drug complex is made up of moieties of sacubitril, a neprilysin inhibitor and valsartan, an ARB. Since sacubitril and valsartan, inhibit neprilysin and block the angiotensin receptor, respectively, the drug molecule can be considered to play a central role by causing a dual inhibition of both the pathways that play an important role in the pathogenesis of HF. It was approved in July 2015 by the US Food and Drug Administration to reduce the risk of cardiovascular death and hospitalization for HF in patients with chronic HF (NYHA Class II-IV) and reduced ejection fraction. Symptomatic hypotension and angioedema were the major side effects reported from clinical trials. The trials are currently being done to study its effects in HF preserved ejection fraction, chronic kidney disease, and aortic stiffness; the results of which are awaited.

AB - Heart failure (HF) is a syndrome whose cardinal symptoms are dyspnea and fatigue leading to a progressive decrease in exercise capacity. Drugs currently used include angiotensin-converting-enzyme inhibitors, angiotensin receptor blockers (ARB), diuretics, alone or in combination, and in the cases where indicated, digoxin. Sacubitril/valsartan represents a new approach to treatment since the drug complex is made up of moieties of sacubitril, a neprilysin inhibitor and valsartan, an ARB. Since sacubitril and valsartan, inhibit neprilysin and block the angiotensin receptor, respectively, the drug molecule can be considered to play a central role by causing a dual inhibition of both the pathways that play an important role in the pathogenesis of HF. It was approved in July 2015 by the US Food and Drug Administration to reduce the risk of cardiovascular death and hospitalization for HF in patients with chronic HF (NYHA Class II-IV) and reduced ejection fraction. Symptomatic hypotension and angioedema were the major side effects reported from clinical trials. The trials are currently being done to study its effects in HF preserved ejection fraction, chronic kidney disease, and aortic stiffness; the results of which are awaited.

UR - http://www.scopus.com/inward/record.url?scp=84978110561&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978110561&partnerID=8YFLogxK

M3 - Review article

AN - SCOPUS:84978110561

VL - 9

SP - 37

EP - 40

JO - Asian Journal of Pharmaceutical and Clinical Research

JF - Asian Journal of Pharmaceutical and Clinical Research

SN - 0974-2441

IS - 4

ER -